EMA Withdrawn: Refludan (lepirudin) — Celgene Europe Ltd.

View source ↗

Summary

EMA withdrew Refludan (lepirudin) from the market in 2012, with thromboembolism and thrombocytopenia as therapeutic areas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia
• Thromboembolism

Drugs mentioned

• Refludan (lepirudin)

Snippet

Status: Withdrawn. Therapeutic area: Thromboembolism;Thrombocytopenia. MAH: Celgene Europe Ltd.. Decision date: 24/04/2012